Fogo, Ch. 20 - Allograft rejection Flashcards

1
Q

What diseases affect the transplant kidney (in addition to primary disease?)

A

Alloimmune disease, drug toxicity, infection, ischemia, and obstruction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

When does acute cellular rejection occur? In how many cases?

A

Affects 10% of transplants, usually 1-6wks post-transplant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the glomerular LM findings in ACR.

A

Some cases can have glomerulitis. CMV promotes a rare, disastrous variant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the interstitial LM findings in ACR.

A

Tubulitis, especially in cortex (>25% involvement is diagnostic of grade I). pleomprhis interstitial infiltrate, edema.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the vascular LM findings in ACR.

A

Endothelialitis (defining of grade II), usually affecting larger arteries and rarely transmural. Necrotizing arteritis notes grade III.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the IF findings in ACR?

A

Interstitial fibrin, C4D in peritubular capillaries (notes AMR).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the EM findings in ACR?

A

Not very helpful; endothelial injury/reactivity and platelet/fibrin aggregates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Contrast the clinical features of AMR with ACR.

A

AMR is acute and less responsive to steroids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are some risk factors for AMR?

A

Elevated PRA, prior transplant, positive crossmatch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the LM findings in AMR?

A

Variable; some have just acute tubular injury or even no LM findings, some have capillary neutrophils or even arterial fibrinoid necrosis and thrombosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the IF findings in AMR? What do they signify?

A

C4d in peritubular capillaries. Notes local activation of the classical complement pathway (derived from C4b).

Can also have IgG/IgM in fibrinoid necrosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the pathophysiology and presentation of hyperacute rejection?

A

Preformed anti-HLA or -ABO antigens, resulting in immediate and irreversible graft failure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the pathologic findings in hyperacute rejection?

A

Same as in AMR (PMNs, C4d). IgM antibodies are seen if the reaction is anti-ABO.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How long do kidney grafts last? What contributes to their failure?

A

Around 9 years for DDKT, over 20 for HLA-matched sibling.

Usually due to chronic rejection, CNI toxicity, vascular disease, and chronic infection and/or reflux.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the glomerular LM findings in chronic AMR?

A

Transplant glomerulopathy: Doubling of GBM, mesangial hypercellularity, endocapillary monocytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the vascular LM findings in chronic AMR?

A

Transplant vasculopathy: Intimal thickening with foamy macrophages, sometimes adventitial infiltrate. Spares arterioles?

17
Q

What are the IF findings in chronic AMR?

A

Usually low-level C4d in PTCs and glomeruli. Maybe some globular Ig and vascular fibrin.

18
Q

What are the EM findings in chronic AMR?

A

Foot process effacement, mesangiolysis. Loss of endothelial fenestrations and multilayering of BM.

19
Q

Describe the staging of chronic AMR.

A

I: Evidence of humoral response without graft dysfunction.

II: C4d deposition, still no damage.

III: Clinical evidence of graft dysfunction.

20
Q

What should be considered in the differential diagnosis for chronic AMR?

A

De novo glomerulonephritides, CIT, post-transplant lymphoproliferative disease.